Skip to main content

Table 3 Clinical values over time of response variables after PAE

From: Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population

Variable 1 Mo (n = 105) 3 Mo (n = 105) 6 Mo (n = 105) 12 Mo (n = 94) 24 Mo (n = 84)  
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD PValues
Age(year) 71.5 ± 12.5 71.5 ± 12.5 71.5 ± 12.5 72.5 ± 11.5 70.5 ± 11.0 _
IPSS(point) 9.5 ± 5.5 8.5 ± 3.0 7.5 ± 4.0 8.0 ± 4.5 9.0 ± 5.5 <0.01
QoL score 2.5 ± 1.0 3.0 ± 0.5 3.0 ± 1.0 2.5 ± 1.5 3.0 ± 1.0 <0.01
PV (mL) 103.8 ± 30.0 72.5 ± 25.0 70.0 ± 15.0 68.5 ± 15.0 69.0 ± 18.0 <0.01
Qmax (mL/s) 14.0 ± 3.5 15.0 ± 4.5 15.5 ± 6.5 14.5 ± 5.0 14.5 ± 3.5 <0.01
PVR (mL) 45.0 ± 20.0 40.0 ± 25.0 35.0 ± 15.0 40.0 ± 20.0 40.0 ± 15.0 <0.01
IIEF-5 (point) 11.0 ± 5.0 10.0 ± 4.0 12.0 ± 3.0 13.0 ± 2.0 10.0 ± 2.5 0.6
  1. IIEF-5 = International Index of Erectile Function short form, IPSS = International Prostate Symptom Score, PSA = prostatic specific antigen, PV = prostate volume, PVR = postvoid residual urine, Qmax=peak urinary flow rate, QoL = quality of life.